Шляхта

Moving around metropolitan areas can present challenges for individuals who are obese or have height limitations, as many public spaces are not designed to accommodate their needs. However, a new law adds weight and height to the list of characteristics that are protected from discrimination in New York City. Aron Ranen has the story.
…

China, where COVID-19 was first identified in humans more than three years ago, expects its current wave of infection to hit as many as 65 million cases per week by late June, according to official accounts of models presented at a medical conference.

While that may be an exhausting number to a post-pandemic world wearied by a still rising toll of 767 million confirmed cases and more than 6.9 million deaths, the predicted onslaught in China comes with less severe symptoms, Wang Guiqiang, director of the Department of Infectious Diseases at Peking University First Hospital, told the official newspaper Beijing Daily.

And, experts say, the outbreak is likely to be confined to China. Raj Rajnarayanan, assistant dean of research and associate professor at the New York Institute of Technology and a top COVID-variant tracker, told Fortune that when it comes to XBB variants, “the rest of the world has seen them all.” But up until recently, “China hasn’t.”

Respiratory disease specialist Zhong Nanshan, who spoke on May 22 at a conference in the southern city of Guangzhou, said the current wave of infections that started in late April was “anticipated.” His modeling suggested that by the end of June, the weekly number of infections will peak at 65 million, according to the official Global Times.

After Beijing relaxed the draconian lockdowns enforced under its “zero-COVID” policy, an omicron variant different from the current one ripped through China in December 2022 and January 2023.

About 80% of China’s 1.4 billion people were infected during that wave, Wu Zunyou, chief epidemiologist at the Chinese Center for Disease Control and Prevention, said in January, CNN reported. Patients packed hospitals and families waited for days to cremate those who died.

The latest COVID wave is something most people do not take seriously, said Mr. Lin, who requested anonymity due to the sensitivity of the issue. The resident of Quanzhou in Fujian province said, “They go about their activities normally and don’t do any protection. No one wears masks.”

Mr. Lin told VOA Mandarin he was infected in mid-December 2022, soon after Beijing lifted the lockdowns that had sent the world’s second-largest economy into a tailspin.

He realized he was infected — again — in May. Mr. Lin said he knew others who were likely reinfected and didn’t even bother to take a COVID test because their symptoms were so mild.

Mr. Zhang, who was infected for the first time in December, told VOA Mandarin he was infected a second time on a business trip to Shanghai and Beijing in May. The Hunan province resident, who asked to use a pseudonym to avoid attracting official attention, thought he had caught a cold because of the air conditioning he encountered on his trip.

But he took a test while still in Beijing and with a positive result, ended up at a hospital where he said a doctor told him, “People all over the country are like this. No need for medical attention at all. Just go home.”

After suffering four days with insomnia, loss of appetite and recurring fever, Mr. Zhang went to another Beijing hospital. Admitted, he was given Paxlovid, an anti-coronavirus drug developed by Pfizer.

“I took the medicine at noon and felt relieved at night,” he told VOA Mandarin.

During his hospital stay, Mr. Zhang said, “All the infectious disease wards were full, and there was a long queue to get an appointment. The hospital used wards of other departments for patients from the Infectious Diseases Department.”

Jin Dong-yan, a biochemistry professor with the Li Ka-shing Faculty of Medicine at the University of Hong Kong, told VOA Mandarin there is not much difference between the current situation in China and in the U.S., but the Chinese media devote more coverage to the outbreak.

Jin said, “In fact, looking at the data, the U.S. has experienced about four peaks after the outbreak last year, but each peak is getting smaller and smaller.”

The United States, by comparison, was reporting more than 5 million cases a week at its most recent peak in January.

The World Health Organization declared COVID-19 over as a global health emergency on May 5.

Like the U.S., China stopped providing weekly case updates in May, making it difficult to know the true extent of the current outbreak.

The U.S. Centers for Disease Control and Prevention recorded more than 1.1 million deaths in the U.S. involving COVID-19 from January 4, 2020, to May 27, 2023. 

In China, from January 3, 2020, to May 31, 2023, there have been almost 100 million confirmed cases of COVID-19, with more than 120,000 deaths reported by Beijing to WHO.

Adrianna Zhang contributed to this report.
…

New advances in the fight against a range of cancers have been revealed at the annual meeting of the American Society of Clinical Oncology (ASCO), which wraps up in Chicago on Tuesday.

Here are some of the announcements that have most excited experts.

Lung cancer

One of the trial results that caused a stir in Chicago has raised hopes for a new weapon against lung cancer, the deadliest of all cancers.

The treatment osimertinib was shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumor.

Developed by the pharmaceutical group AstraZeneca, the daily pill targets patients with non-small cell cancer — by far the most common type — as well as a mutation of their epidermal growth factor receptor, or EGFR.

Iris Pauporte, head of research at France’s League Against Cancer, told AFP the advance was a “big ray of hope” for this type of cancer, for which progress has been slow.

Muriel Dahan, head of research at Unicancer, said that if the results are confirmed, it “should change” common practice in treating this kind of lung cancer.

Systematic testing for the EGFR mutation would also become necessary for lung cancer patients, she added.

Brain cancer

Another treatment, called vorasidenib, was found to significantly prolong the progression-free survival of patients with brain tumor glioma, according to clinical trial results.

The daily pill, developed by French pharma firm Servier, aims to block an enzyme responsible for the progression of some brain cancers, which have been particularly difficult to treat.

Patrick Therasse, Servier’s vice-president of oncology research, told AFP that there “have been few therapeutic advances for brain tumors over the last 20 years.”

“Thanks to our targeted treatment, patients avoided cancer progression for 27.7 months, compared to 11.1 months” for those taking a placebo, he added.

Fabrice Andre, head of research at France’s Gustave Roussy cancer center, said “precision medicine opens a door for a disease for which there was nothing until now.”

“It means that science can unblock situations that were catastrophic,” he told AFP.

Unicancer’s Dahan said it was important to “remain cautious” but added that “this could become the new therapeutic standard — depending on further trials.”

Breast cancer

Preliminary trial results also released in Chicago indicated the drug ribociclib reduced the risk of breast cancer recurring by 25 percent for a large group of early-stage survivors.

The drug, developed by Swiss pharmaceutical maker Novartis, is already widely approved around the world. It was tested in combination with hormonal therapy.

ASCO expert Rita Nanda said it was a “very important and practice-changing clinical trial.”

Cervical cancer

There was also good news for patients with early-stage cervical cancer with a low risk of progression.

There was no greater risk of the cancer returning for patients who get a simple hysterectomy, in which the uterus and cervix are removed, than a radical hysterectomy, in which the uppermost part of the vagina is also removed, according to phase three trials.

League Against Cancer’s Pauporte said this was “good news,” adding that “it shows that it’s not just progress involving drugs that was important.”

Ovarian cancer

A trial also presented at ASCO showed that taking the antibody treatment mirvetuximab soravtansine significantly improved the survival rate of patients with ovarian cancer, a particularly deadly form of cancer.

ASCO expert Merry Jennifer Markham said the treatment “demonstrates progress and offers hope for these patients.”

Rectal cancer

Study results released in Chicago indicated that patients with locally advanced rectal cancer could receive chemotherapy without getting radiation therapy before undergoing surgery.

This would spare patients from the brutal side effects of radiation.

Vaccines

Vaccines that treat existing cancer have long been a goal of the medical community.

Preliminary studies announced at the ASCO meeting involved vaccines targeting lung cancer, head and neck cancers, brain tumor glioblastoma and the cancer-causing HPV virus.

Christophe Le Tourneau, an oncologist at France’s Curie Institute which presented a study about a vaccine for a certain form of HPV, said there has been “significant technological progress” in the area recently.

“Therapeutic vaccines, we talk about them more and more, and there are more and more trials in progress,” he said.
…

Global leaders in the battle against global warming convened in Bonn, Germany, on Monday for the start of the final phase of a two-year long assessment of the progress being made to limit rising temperatures.

The annual Bonn Climate Change Conference is part of the “global stocktake” — a process by which countries around the world assess how much progress has been made toward compliance with the 2015 Paris Agreement, a worldwide effort to prevent global temperatures from exceeding 1.5 degrees Celsius above the pre-industrial era average.

“The global stocktake is an ambition exercise. It’s an accountability exercise. It’s an acceleration exercise,” U.N. Climate Change Executive Secretary Simon Stiell said in a statement. “It’s an exercise that is intended to make sure every Party is holding up their end of the bargain, knows where they need to go next and how rapidly they need to move to fulfill the goals of the Paris Agreement.”

However, Stiell warned that the findings will only be meaningful if they are paired with action.

“The global stocktake will end up being just another report unless governments and those that they represent can look at it and ultimately understand what it means for them and what they can and must do next. It’s the same for businesses, communities and other key stakeholders,” he said.

The stocktake will conclude in November, when the annual U.N. Climate Change Conference (COP28) is held in Dubai, United Arab Emirates.

Stocktake process

The global stocktake is a two-year process that happens once every five years, as dictated by the Paris Agreement. It has three parts: an information collection and preparation phase, a technical assessment and a consideration of the process’s outputs.

The stocktake began in 2021, with countries, NGOs, experts and other stakeholders gathering information about efforts currently underway to slow global warming. This includes efforts by individual countries to meet the emission-reduction goals they have agreed to at previous COP gatherings — known as nationally determined contributions (NDCs) — as well as challenges and barriers to meeting those goals, and data about new mitigation techniques.

At last year’s Bonn Climate Conference, technical experts began to assess the findings, a process meant to be finalized over this year’s 10-day gathering.

The consideration of the findings will begin immediately following the conference and will be translated into recommendations for further action meant to be finalized in Dubai later this year.

No mystery

While the final details of the global stocktake will not be published until later this year, there is little mystery about what the process is likely to uncover. An interim report published in March found that progress has been “significant yet inadequate” in terms of reaching the goals set out in the Paris Agreement.

“While the remarkable speed with which the Paris Agreement entered into force in 2016 demonstrates a broad commitment, and Parties are making progress in implementation, we as a global community are not on track to meet its long-term goals,” the report found.

Still, experts said that there are reasons for optimism.

“The big value out of the global stocktake is that it’s also meant to be telling us not only where we are and where we need to be, but how to get there. What we’re hearing through the process so far is that there are solutions across all sectors and all [greenhouse] gases,” Maggie Ferrato, a manager for global climate cooperation at the Environmental Defense Fund, told VOA.

“And really the challenge is to kind of distill really clear signals from the wealth of information that’s out there on the highest impact opportunities that should be incorporated into Nationally Determined Contributions in the next round.”

More upbeat assessment

The Bonn Conference comes just a few weeks after a pair of reports from U.N.-affiliated research organizations painted grim pictures of the planet’s climate future.

In March, the Intergovernmental Panel on Climate Change warned that the planet is getting close to being unable to avoid a temperature increase of more than 1.5 degrees Celsius and predicted that more negative consequences of global climate change will soon become apparent. It said that the changes will frequently harm poor and vulnerable populations across the globe, many of which have contributed little to global warming.

Last month, the World Meteorological Organization issued a report that found a two-thirds chance the world will experience at least one year of temperatures averaging more than 1.5 degrees over the pre-industrial average within the next five years.

Michael Mehling, deputy director of the Center for Energy and Environmental Policy Research at the Massachusetts Institute of Technology, told VOA that organizers of the Bonn Conference and of the COP process in general seem to realize unremitting gloom about the climate future may be doing more harm than good.

“I think there’s certainly a realization that just always saying, ‘We’re far behind. Everything looks terrible,’ is losing some impact,” he said.

Mehling said that he anticipates a report that recognizes that progress has been made and that achieving a less ambitious goal of keeping warming below 2 degrees — a level that scientists warn could be catastrophic — is achievable.

“I would probably anticipate some sort of a split message that suggests that we have to continue holding the line and staying [focused] on 2 degrees, but we can achieve that,” he said. “But it doesn’t look good for 1.5, unless we dramatically change what we’re doing. That’s what I expect to be the headline message.”
…